Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Earnings Routine +

MedMira Reports Third Quarter Results FY2026

By The Northwire Desk — AI Analysis Jun 29, 2026 · 20:00 MIR · 0.07 MedMira Inc.
MIR · Price

Executive Summary

  • MedMira Inc. reported its financial results for the third quarter of fiscal year 2026 (ended April 30, 2026), showing a significant increase in revenue and gross profit compared to the previous quarter, while narrowing its net loss year-over-year.
  • The company advanced the regulatory approval process for its Multiplo® Complete Syphilis test, receiving initial feedback from Health Canada and completing the second phase of clinical trials.
  • International expansion efforts are underway, including regulatory submissions in Australia under the Mutual Recognition Agreement and evaluations in selected EMEA markets.

Key Details

  • Revenue: $241,189 for Q3 FY2026, compared to $24,503 in Q2 FY2026 and $59,117 in Q3 FY2025.
  • Gross Profit: $176,409 for Q3 FY2026, compared to $18,132 in Q2 FY2026 and $43,011 in Q3 FY2025.
  • Operating Expenses: $441,218 for Q3 FY2026, compared to $423,180 in Q2 FY2026 and $772,776 in Q3 FY2025.
  • Net Loss: $483,660 for Q3 FY2026, compared to a net loss of $657,552 for the same period last year.
  • Assets: Decreased by $176,935 between Q2 and Q3 FY2026, primarily due to depreciation expense on corporate assets.
  • Liabilities: Increased by $306,725 between Q2 and Q3 FY2026; current liabilities increased by $263,164 due to higher accounts payable and accrued liabilities.
  • Loans in Default: Decreased by $9,522 due to currency fluctuations (USD and Swiss Franc); long and short-term debts are currently under negotiation for restructuring.
  • Working Capital Deficit: Recorded a deficit of $365,147, an increase of 2% compared to the previous quarter.
  • Regulatory Updates: Received initial feedback from Health Canada for the Multiplo® TP/nTP Antibody Test; second phase of clinical trials completed with data to be submitted to support the existing application.
  • International Expansion: Initiated regulatory approval processes in Australia under the Mutual Recognition Agreement and is pursuing similar initiatives in selected EMEA markets.

Notable Quotes

  • No direct quotes from the CEO or President were included in the provided text.
Read the original news release →

More from MedMira Inc.

Apr 01, 2026 · 22:00

MedMira Reports Second Quarter Results FY2025

Earnings Dec 30, 2025 · 20:00

MedMira Reports First Quarter Results FY2026

Earnings Nov 28, 2025 · 21:00

MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

Earnings